340B Drug Pricing Program
AHA expresses profound concern about actions Novartis Corporation Global, is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions Merck is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
The Centers for Medicare & Medicaid Services (CMS) today released the calendar year (CY) 2021 outpatient prospective payment system (OPPS)/ambulatory surgical center (ASC) proposed rule.
AHA statement on the CY OPPS proposed rule from Executive Vice President Tom Nickels.
The U.S. Court of Appeals for the District of Columbia Circuit overturned a 2018 district court decision that found the Department of Health and Human Services exceeded its statutory authority when it reduced 2018 and 2019 Medicare payment rates for many hospitals in the 340B Drug Pricing Program…
A statement on the 340B court decision from the AHA, AAMC and America’s Essential Hospitals
AHA expresses concern regarding recent action taken by three major drug manufacturers – Eli Lilly and Co., Merck and Sanofi – to limit the distribution of certain 340B drugs to our hospital members.
A panel of 4 experts discussed federal policy emerging from Congress and the Administration under COVID-19 focusing on rural health priorities and took questions from the audience. They reviewed emergency funding, Medicare and Medicaid payment improvements, telehealth, regulatory relief, 340B drug…
The AHA urged the Department of Health and Human Services and the Health Resources and Services Administration to provide flexibility in the administration of the 340B Drug Pricing Program to better enable these hospitals to serve their communities during the COVID-19 national emergency.
The AHA submitted its comments to the Office of Management and Budget regarding the Centers for Medicare & Medicaid Services (CMS) plans to collect pricing data on Hospital Survey for Specified Covered Outpatient Drugs (SCODs) from all hospitals that participate in the 340B Drug Pricing Program…